Positioning the Novel Therapeutics in Diabetes Care: Time to Integrate the Recommendations.

Cardiovascular outcome trials in patients with type 2 diabetes (T2DM) at high risk have led to remarkable advances in our understanding of the efficacy of glucagon-likepeptide-1 receptor agonists(GLP-1RA) and sodium glucose cotransporter 2 inhibitors(SGLT2i) to reduce cardiorenal events. The American Diabetes Association (ADA), the European Association for the Study of Diabetes (EASD), and the European Society of Cardiology have recently published recommendations for management of such patients. We are concerned that ongoing discussions focusing on the differences between the endocrinologists’ consensus and the cardiologists’ guidelines are contributing to clinical inertia and thereby effectively denying evidence-based treatments advocated by both to people with T2DM and CV disease or heart failure. A subset of members of both writing groups were convened to emphasise where commonalities exist and to propose an integrated paradigm that encompasses the views incorporated in the ESC and ADA/EASD management approaches.